Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity

CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammato...

Full description

Saved in:
Bibliographic Details
Published in:International journal of peptide research and therapeutics 2019-06, Vol.25 (2), p.535-540
Main Authors: Sadeghian-Rizi, Tahereh, Behdani, Mahdi, Khanahmad, Hossein, Ghasemi-Dehkordi, Pooria, Mirmohammad Sadeghi, Hamid, Jahanian-Najafabadi, Ali
Format: Article
Language:English
Subjects:
Animal Anatomy
Autoimmune diseases
Biochemistry
Biomedical and Life Sciences
Chemokines
CXC chemokines
CXCL10 protein
CXCR3 protein
Enzyme-linked immunosorbent assay
Gel electrophoresis
Histology
Immunization
Immunoglobulin G
Life Sciences
Medical treatment
Membrane reactors
Molecular Medicine
Morphology
Multiple sclerosis
Nanobodies
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Polyclonal antibodies
Polymer Sciences
Protein G
Sodium lauryl sulfate
Therapeutic applications
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CXCL10 chemokine is a member of CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, and inflammatory and autoimmune diseases. It has been put forward as a potential biomarker and therapeutic target in diagnosis and treatment of these diseases. In the present study, production of camel heavy chain antibodies (HCAbs) specific for the CXCL10 is reported. In this regard, recombinant CXCL10 was used for immunization of camel and subsequently the CXCL10 HCAbs were obtained. Afterwards, three subclasses of IgG were separated using protein A and protein G affinity columns, characterized with SDS-PAGE and confirmed for specific binding to the CXCL10 using ELISA. These IgG subclasses successfully recognized CXCL10 and a strong and specific reactivity towards CXCL10 were observed. Therefore, the selected HCAbs and their corresponding expression library could be used to develop a recombinant variable domain of these HCAbs (nanobody or VHH) as a new possible strategy for treatment of multiple sclerosis and other autoimmune diseases.
ISSN:1573-3149
1573-3904
DOI:10.1007/s10989-018-9697-6